| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - |
| 05 Nov 2026 | 10-Q |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 16 Oct 2026 |
Form 4/A: McCarthy Sean A., Director
Received 101,793 shares by exercise or conversion ($162K) · Sold 101,793 shares ($462K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | S-8 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - |
| 06 Aug 2026 | 10-Q |
| 05 Aug 2026 |
Form 4: Carvajal Alejandra, Chief Legal Officer
Received 100,000 shares as a grant or award · Granted 450,000 Stock Option (Right to Buy) |
| 05 Aug 2026 |
Form 3: Carvajal Alejandra, Chief Legal Officer
No securities owned |
| 03 Aug 2026 | SCHEDULE 13G |
| 30 Jul 2026 |
Form 4: Fuchs Charles S., Director
Granted 118,000 Stock Option (Right to Buy) |
| 30 Jul 2026 |
Form 3: Fuchs Charles S., Director
No securities owned |
| 27 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 22 Jun 2026 |
Form 4: Su Zhen, Director
Granted 59,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
1.1 Purposes. This CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan, as amended by the Board on March 18, 2026 (this “Plan”), is effective as of the date the stockholders of the Company approve this Plan. The pur... |
Loading...